Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
about
Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repairAutomated mass action model space generation and analysis methods for two-reactant combinatorially complex equilibriums: an analysis of ATP-induced ribonucleotide reductase R1 hexamerization data.High expression of ribonucleotide reductase subunit M2 correlates with poor prognosis of hepatocellular carcinoma.Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer.ERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and/or gemcitabine.Correlated tissue expression of genes of cytoplasmic and mitochondrial nucleotide metabolisms in normal tissues is disrupted in transformed tissuesCyclins and cell cycle control in cancer and disease.Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression.Genomic alterations in neuroendocrine cancers of the ovary.Drug transporter pharmacogenetics in nucleoside-based therapies.Gemcitabine-loaded innovative nanocarriers vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity.Targeting ribonucleotide reductase for cancer therapy.Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies.Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy.Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metabolomic analyses in PK9 cells.The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines.Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd).Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy.Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.Effects of DCK knockdown on proliferation, apoptosis and tumorigenicity in vivo of cervical cancer HeLa cells.Downregulation of ribonucleotide reductase subunits M2 induces apoptosis and G1 arrest of cervical cancer cells.Nucleoside transporters are widely expressed in ovarian carcinoma effusions.Proteomic and Bioinformatic Studies for the Characterization of Response to Pemetrexed in Platinum Drug Resistant Ovarian Cancer.Identification of key candidate genes and small molecule drugs in cervical cancer by bioinformatics strategyNucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism
P2860
Q24336569-0D05F613-CAC6-4F6F-BA5C-CB69E5119358Q33517852-E0C0BF4A-0D88-4237-91C1-CCAC2891EC10Q34432197-268F086E-FE41-4936-BC19-162BBE8B3D60Q36152246-E24E4F6E-A999-4E06-82C9-094C139DBC29Q36243941-5F36B483-B7A3-41DD-83CB-6BAAF56B4763Q36298243-CE8A1EB2-A2E6-4AE9-B8E3-58079C7C03C7Q36796438-434BCCBF-57F4-4AE9-B9FD-1DE7ACF1F964Q36931187-DA686D6E-7743-4BEB-BB06-9724BD99CF50Q37212060-CC8B4AA7-3980-4430-AB66-2817EEE0F7DBQ37760954-B4573254-E475-4B87-9745-07CBE30C61F6Q37955222-AFF5667D-3D73-443F-9A25-185B5FD6B1D6Q38148222-A6FF94F2-043D-4BEE-84BA-DE382F52B15DQ38218536-61E9C8A3-1F86-4101-A027-80B0314ACC08Q38728212-DAD2E982-6D21-4A9B-B9D8-534746D388E8Q39146064-B7AB1BE2-4324-4060-A214-823C8CB8BEFBQ39379544-7CE8E49D-953F-4773-9D1B-ACF4FFDA1B38Q39422598-6152D69C-7321-4DEA-8E89-5D7B02AA55FAQ39612438-06AD1DC4-E54A-42EE-B762-94A02A9E9913Q40996472-EEC5C195-043C-4707-AB9D-E3C0CC714B4BQ44592465-3DF40988-F452-4668-A9C5-1CDA66ED56DAQ50500879-CD9F72D9-208C-4FCB-BFBE-FA4D8DCE3688Q52725569-6E17F76A-6FD8-46D1-A2C8-61E8F72851FBQ53148496-E441B8F5-6D03-42F7-B6FF-74EE33264CD3Q55311424-A2FDD2FB-78BB-41B8-A1A0-3C9C02A75501Q57075019-27571A71-AC84-4403-AA30-425212184769Q57175017-0D9D754A-F70C-44C1-92A4-B47EBA2DEBEF
P2860
Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Expression of nucleoside trans ...... mes in primary ovarian cancer.
@ast
Expression of nucleoside trans ...... mes in primary ovarian cancer.
@en
Expression of nucleoside trans ...... mes in primary ovarian cancer.
@nl
type
label
Expression of nucleoside trans ...... mes in primary ovarian cancer.
@ast
Expression of nucleoside trans ...... mes in primary ovarian cancer.
@en
Expression of nucleoside trans ...... mes in primary ovarian cancer.
@nl
prefLabel
Expression of nucleoside trans ...... mes in primary ovarian cancer.
@ast
Expression of nucleoside trans ...... mes in primary ovarian cancer.
@en
Expression of nucleoside trans ...... mes in primary ovarian cancer.
@nl
P2093
P1476
Expression of nucleoside trans ...... ymes in primary ovarian cancer
@en
P2093
Cristiano Ferlini
Giovanni Scambia
Marco Petrillo
Mario Del Tacca
Sara Nannizzi
Simona Ricciardi
Valentina Mey
P2888
P304
P356
10.1007/S00280-009-1073-Y
P577
2009-07-29T00:00:00Z
P6179
1038846435